Covid Vaccine Race

An expert stresses the need to consider individuals' worry over information—and even their history with systemic biases.

Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.

The 2 revisions made to the EUA pertain to the number of doses allotted to the current vials containing the vaccine, and allow a new vial that has a maximum of 15 doses.

The companies are now seeking a Biologics License Application with the FDA, which would allow it to become more greatly available for adults in the US.

A manufacturing plant that was set to produce the Janssen (Johnson & Johnson) vaccine mixed up the ingredients of 2 vaccines.

The pivotal phase 3 data, based off 18 reported cases among placebo patients, includes the companies' intention to request authorization for adolescents aged 12-15 years old.

The country’s federal health agency decided upon this action based on the small number of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) incidents in Europe, which are being investigated.

Cases have increased by 16%, while 50 million have now been fully vaccinated. Federal leadership is asking Americans to hold on longer.

Intermediate-dose prophylactic anticoagulation did not improve mortality or venous or arterial thrombosis in patients with COVID-19 in the ICU compared with standard dosing, a new study found.

The Moderna and Pfizer-BioNTech vaccines are highly effective and transmission is unlikely.

England starts easing lockdown restrictions in hopes of removing most by early summer.

The companies announced they are expanding their study in children ages 6 months to 11 years old.

The president updated his goal during his press conference this afternoon.

Serum neutralizing antibodies to SARS-CoV-2 from infection or vaccination were found to recognize and act against new variants of the virus.

Overnight, the company restated it had a 76% efficacy against symptomatic disease and is looking to file an Emergency Use Authorization (EUA) with the Food and Drug Administration (FDA).

A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”

Facilities in Connecticut had an outbreak prior to vaccinating their residents, which in turn controlled the spread effectively.

Reproduction number should govern allocation of the shot, researchers say.

New polls shows confidence in AstraZeneca vaccine plummets in Europe.

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

COVID-19 vaccine development demanded an adults-first approach. A year in, children are being invited to participate in trials in hopes of getting the pediatric population vaccinated later this year.

Regardless of symptom status, the rate of participants positive for pan-immunoglobulins with neutralizing antibodies at baseline remained stable throughout 2020.

The new findings support increased protection from reinfection up to 6 months after first testing positive, though older patients are at greater risk of reinfection.

Researchers and clinicians continually failed to connect with the greater public on matters of the pandemic. What drove the divide between the already distanced groups?

A 2-dose vaccination regimen did not show protection against mild-to-moderate disease due to the B.1.351 variant.

The vaccine is currently authorized for use under an EUA in individuals 18 years of age and older.

There are many reasons for COVID-19 vaccine hesitancy, including its side effects. Here is an examination of side effects in those who have been vaccinated.

Number of cases surge in the pacific island nation of Papua New Guinea.

The data additionally show a 94% prevention against asymptomatic SARS-CoV-2 infection, at a time when the country's dominant strain was the B.1.1.7 variant.

France announces a relaxation on restrictions involving international travel outside the EU.